Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 8.82B +49.0% |
| Revenue (ttm) | 776.57M +56.9% |
| Net Income | -191.64M |
| EPS | -3.76 |
| Shares Out | 52.38M |
| PE Ratio | n/a |
| Forward PE | 798.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 894,483 |
| Open | 170.18 |
| Previous Close | 170.08 |
| Day's Range | 166.12 - 170.64 |
| 52-Week Range | 118.71 - 260.19 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 283.63 (+68.48%) |
| Earnings Date | Nov 2, 2026 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price target is $283.63, which is an increase of 68.48% from the latest price.
News
Axsome Therapeutics price target lowered to $295 from $297 at RBC Capital
RBC Capital lowered the firm’s price target on Axsome Therapeutics (AXSM) to $295 from $297 and keeps an Outperform rating on the shares as part of a broader research note…
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target lowered to $267 from $280 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Axsome Therapeutics (AXSM) to $267 from $280 and keeps a Buy rating on the shares. The firm updated its estimates for Auvelity…
Axsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Axsome Therapeutics (AXSM) to $247 from $251 and keeps an Equal Weight rating on the shares after having hosted a call with…
Axsome Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Axsome Therapeutics (AXSM) with a Buy rating with a price target of $285, up from $200. The firm is positive on the company’s near-term revenue growth…
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day
The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care par...
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...
Axsome Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Q2 revenue grew 46% year-over-year to $218.4 million, driven by Auvelity's strong performance and new ADA indication. The pipeline remains robust with seven ongoing trials and an NDA for AXS-12 under review. Expanded sales force and strong IP position support sustained growth.
Axsome Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-originated innovation and AI are shaping R&D and commercial operations, while AUVELITY's launch shows strong growth, especially in the Medicare 65+ segment. Conservative market assumptions support an $8 billion peak sales target, with robust pipeline progress and a clear path to profitability.
Axsome Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted robust commercial momentum for AUVELITY in MDD and Alzheimer's agitation, with significant sales force expansion and strong early feedback. Multiple late-stage pipeline catalysts are expected through 2026–2027, and broad market access supports continued growth.
Axsome Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Robust commercial growth is driven by AUVELITY's expanded sales force and new Alzheimer's agitation indication, with strong Medicare coverage and early positive feedback. The late-stage pipeline includes multiple phase III trials, and financials show a strong cash position and improving gross-to-net trends. Capital allocation focuses on top-line growth and strategic business development.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...
Axsome pullback brings attractive entry point, says H.C. Wainwright
H.C. Wainwright keeps a Buy rating on Axsome Therapeutics (AXSM) with a $290 price target after the company announced the first patient has been dosed in the SUMMIT Phase 3…
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target raised to $316 from $306 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $316 from $306 and keeps an Outperform rating on the shares. The firm views the stock…
Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Axsome Therapeutics (AXSM) to $297 from $304 and keeps an Outperform rating on the shares after the firm’s catch…
Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $251 from $242 and keeps an Equal Weight rating on the shares. The firm adjusted its estimates following…
Axsome Therapeutics price target raised to $275 from $260 at Guggenheim
Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $275 from $260 and keeps a Buy rating on the shares, citing Axsome’s continued strong product performance, a growing…
Axsome Therapeutics price target raised to $256 from $255 at Wells Fargo
Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $256 from $255 and keeps an Overweight rating on the shares. The firm notes the uptake of Auvelity…
Axsome Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw 46% revenue growth to $218M, led by AUVELITY and SUNOSI, with AUVELITY's Alzheimer's agitation launch driving strong new-to-brand prescription growth. The neuroscience pipeline advanced, and cash reserves of $320M are expected to fund operations into profitability.
Axsome Therapeutics Earnings release: Q2 2026
Axsome Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Axsome Therapeutics Slides: Q2 2026
Axsome Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Axsome Therapeutics Quarterly report: Q2 2026
Axsome Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Axsome Therapeutics reports Q2 EPS (99c), consensus (85c)
Reports Q2 revenue $218.38M, consensus $221.78M. “The second quarter was highly productive for Axsome. Our commercial business grew robustly, driven by strong underlying demand for our products, and w...
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 202...